Elanco to carve out microbiome R&D platform; appoints new innovation chief

Elanco Animal Health Inc

Ellen de Brabander, Ph.D., named EVP of Innovation and Regulatory Affairs, effective Oct 18, 2021.
Aaron Schacht will lead the carve-out of Elanco's microbiome R&D platform into an independent biopharma company.
Carve-out expected by Q1 2022; Elanco may retain minority stake; J.P. Morgan advising.
Elanco reaffirms 2025 innovation revenue target of $600–700M, supported by KindredBio acquisition and pipeline.
Pet health portfolio increased as a percentage of pipeline; focus on high-value late-stage candidates.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Aaron Schacht

Executive Vice President of Innovation, Regulatory, and Business Development

ELAN · Elanco Animal Health Inc

Effective: 2021-10-18
Filed: October 5, 2021, 7:59 PM ET

Aaron Schacht, Elanco’s Executive Vice President of Innovation, Regulatory, and Business Development, is transitioning to lead the potential carve-out of Elanco’s microbiome R&D platform

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Aaron Schacht changed role as Executive Vice President of Innovation, Regulatory, and Business Development at Elanco Animal Health Inc.

Action: transitioning
Role: Executive Vice President of Innovation, Regulatory, and Business Development

Exact text from the filing

Aaron Schacht, Elanco’s Executive Vice President of Innovation, Regulatory, and Business Development, is transitioning to lead the potential carve-out of Elanco’s microbiome R&D platform

View on SEC.gov

Elanco Animal Health Inc filing history →

Source: SEC EDGAR

accession 0001104659-21-122758

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.